Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model

STAR Protoc. 2022 Nov 4;3(4):101818. doi: 10.1016/j.xpro.2022.101818. eCollection 2022 Dec 16.


Human killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail (KIR3DL3) is expressed on natural killer (NK) cells and is a newly identified inhibitory receptor for B7 family member HERV-H LTR-associating protein 2 (HHLA2). Here, we summarize the isolation and expansion of KIR3DL3+ human NK cells, and in vitro functional characterization of in-house anti-KIR3DL3 monoclonal antibody (mAb). We also describe a human NK cell-based xenogeneic lung tumor model for testing the therapeutic activity of KIR3DL3 blockade in vivo. For complete details on the use and execution of this protocol, please refer to Wei et al. (2021).

Keywords: Cancer; Cell Biology; Cell isolation; Cell-based Assays; Health Sciences; Immunology.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Immunoglobulins
  • Killer Cells, Natural*
  • Lung Neoplasms* / drug therapy
  • Receptors, KIR / metabolism


  • Receptors, KIR
  • HHLA2 protein, human
  • Immunoglobulins
  • KIR3DL3 protein, human